MCK241115P370000
- 1.40
- 0.000.00%
McKesson Newsroom
McKesson Analyst Ratings
Citi Maintains McKesson(MCK.US) With Buy Rating, Raises Target Price to $713
Analysts Conflicted on These Healthcare Names: McKesson (MCK), Fate Therapeutics (FATE) and Voyager Therapeutics (VYGR)
Argus Adjusts Price Target on McKesson to $660 From $570
Barclays Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $668
Evercore Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $680
A Quick Look at Today's Ratings for McKesson(MCK.US), With a Forecast Between $612 to $688
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), McKesson (MCK) and Enhabit, Inc (EHAB)
Mizuho Adjusts Price Target on McKesson to $550 From $530, Maintains Neutral Rating
McKesson Is Maintained at Outperform by Evercore ISI Group
A Quick Look at Today's Ratings for McKesson(MCK.US), With a Forecast Between $535 to $688
McKesson Analyst Ratings
Barclays Remains a Buy on McKesson (MCK)
Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Henry Schein (HSIC) and McKesson (MCK)
McKesson's Strong Q2 Performance and Upward EPS Guidance Justify Buy Rating
Barclays Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $616
BofA Securities Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $635
Analysts Conflicted on These Healthcare Names: Medpace Holdings (MEDP), McKesson (MCK) and Glaukos (GKOS)
BofA Securities Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $635
Morgan Stanley Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $612